Obseva (NASDAQ:OBSV) was upgraded by investment analysts at TheStreet from a “d+” rating to a “c-” rating in a research report issued on Thursday.
Several other research analysts have also recently commented on OBSV. HC Wainwright set a $30.00 price target on Obseva and gave the company a “buy” rating in a research report on Monday, July 16th. Zacks Investment Research lowered Obseva from a “buy” rating to a “hold” rating in a research note on Wednesday. BMO Capital Markets upped their price objective on Obseva from $23.00 to $31.00 and gave the company an “outperform” rating in a research note on Monday, June 18th. Wedbush assumed coverage on Obseva in a research note on Monday, August 6th. They issued an “outperform” rating and a $34.00 price objective on the stock. Finally, Credit Suisse Group assumed coverage on Obseva in a research note on Thursday, July 19th. They issued an “outperform” rating and a $24.00 price objective on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.00.
Shares of NASDAQ OBSV opened at $16.30 on Thursday. Obseva has a 52 week low of $8.79 and a 52 week high of $20.35. The company has a market cap of $656.95 million, a P/E ratio of -7.24 and a beta of 1.49.
Obseva (NASDAQ:OBSV) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.05. Equities analysts predict that Obseva will post -1.93 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the business. VHCP Management II LLC raised its stake in Obseva by 5.1% in the second quarter. VHCP Management II LLC now owns 2,252,460 shares of the company’s stock valued at $34,102,000 after buying an additional 108,617 shares during the period. FMR LLC bought a new position in shares of Obseva during the second quarter worth approximately $27,254,000. First Manhattan Co. increased its stake in shares of Obseva by 50.9% during the second quarter. First Manhattan Co. now owns 1,508,966 shares of the company’s stock worth $22,845,000 after purchasing an additional 508,966 shares during the period. Vivo Capital LLC bought a new position in shares of Obseva during the second quarter worth approximately $14,005,000. Finally, Acuta Capital Partners LLC bought a new position in shares of Obseva during the second quarter worth approximately $6,424,000. Hedge funds and other institutional investors own 68.26% of the company’s stock.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Story: What Does Beta Mean In Stock Selection
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.